Summary
Multiple myeloma remains one of oncology's most challenging blood cancers, but the treatment landscape is undergoing a seismic shift.
With the multiple myeloma market valued at USD 28.7 billion in 2025 and projected to grow steadily through 2036, the pipeline has never been more robust or more consequential.
Seven late-stage therapies, namely Arcellx/Gilead’s Anito-cel, AbbVie’s ABBV-383, Bristol Myers Squibb/Celgene’s Iberdomide, Mezigdomide, and Arlo-cel, AbbVie and Roche’s VENCLEXTA, and AstraZeneca’s AZD0120, are now closing in on regulatory approval, each representing a distinct and innovative approach to tackling this incurable disease.
Mu...
